Section 720.50 Drugs and
Devices
a) Drugs: Name.
The name by
which a drug is designated shall be clearly distinguishing and differentiating
from any name recognized in an official compendium unless such drug complies in
identity with the identity prescribed in an official compendium under such
recognized name.
b) The term "drug defined in an official compendium"
means a drug having the identity prescribed for a drug in an official
compendium.
c) A statement that a drug defined in an official compendium
differs in strength, quality or purity from the standard of strength, quality
or purity set forth for such drug in an official compendium shall show all the
respects in which such drug so differs, and the extent of each such difference.
d) Drugs and Devices: Labeling, Misbranding.
Among
representations in the labeling of a drug or device which render such drug or
device misbranded is a false or misleading representation with respect to
another drug or device or a food or cosmetic.
e) The labeling of a drug which contains two or more ingredients
may be misleading by reason (among other reasons) of the designation of such
drug in such labeling by a name which includes or suggests the name of one or
more but not all such ingredients, even though the names of all such
ingredients are stated elsewhere in the labeling.
f) Drugs and Devices: Place of Business.
If a drug or
device is not manufactured by the person whose name appear on the label, the
name shall be qualified by a phrase which reveals the connection such person
has with such drug or device, such as "Manufactured for and Packed by ____________,"
"Distributed by ____________," or other similar phrase which
expresses the facts.
g) The statement of the place of business shall include the
street address, if any, of such place, unless such street address is shown in a
current city directory or telephone directory.
h) Where a person manufactures, packs or distributes a drug or
device at a place other than his principal place of business, the label may
state the principal place of business in lieu of the actual place where each
package of such drug or device was manufactured or packed or is to be
distributed, if such statement is not misleading in any particular.
i) The requirement that the label shall contain the name and
place of business of the manufacturer, packer or distributor shall not be
considered to relieve any drug or device from the requirement that its label
shall not be misleading in any particular.
j)
1) The statement of the quantity of the contents of a package of
a drug shall reveal the quantity of such drug in the package, exclusive of
wrappers and other material packed with such drug.
2) The statement shall be expressed in the terms of weight, measure,
numerical count, or a combination of numerical count and weight or measure,
which are generally used by consumers and users of such drug to express
quantity thereof and which give accurate information as to such quantity. But
if no general usage in expressing accurate information as to the quantity of
such drug exists among consumers and users thereof, the statement of the
quantity of a drug which is not in tablet, capsule, ampule or other unit form
shall be in terms of weight if the drug is solid, semisolid or viscous, or in
terms which if in such unit form shall be in terms of the numerical count of
such units, supplemented, when necessary to give accurate information as to the
quantity of such drug in the package, by such statement (in such terms, manner
and form as are not misleading) of the weight or measure of such units, or of
the quantity of each active ingredient in each such unit as will give such
information.
k) The statement of the quantity of a device shall be expressed
in terms of numerical count.
l) A statement of weight shall be in terms of the avoirdupois
pound, ounce and grain, or of the kilogram, gram and milligram. A statement of
liquid measure shall be in terms of the United States gallon of 231 cubic
inches and quart, pint, fluid ounce and fluid dram subdivisions thereof, or of
the liter, milliliter or cubic centimeter, and shall express the volume at 68º
Fahrenheit (20º Centigrade).
m) Statements of the quantity of a drug shall contain only such
fractions as are generally used in expressing the quantity of such drug. A
common fraction shall be reduced to its lowest terms; a decimal fraction shall
not be carried out to more than three places, except in the case of a statement
of the quantity of an active ingredient in a unit of a drug.
n)
1) Unless made in accordance with the provisions of subsection
(n)(2) of this Section, a statement of the quantity of a drug, in the terms of
weight or measure applicable to such drug under the provisions of subsection
(j)(2) of this Section, shall express the number of the largest unit specified
in subsection (l) of this Section which is contained in the package (for
example, the statement on the label of a package which contains one pint of a
drug shall be "1 pint" and not "16 fluid ounces"). Where
such number is a whole number and a fraction, there may be substituted for the
fraction its equivalent in smaller units, if any smaller is specified in
subsection (l) of this Section (for example, 1¼ pounds may be expressed as
"1 pound 4 ounces"). The stated number of any unit which is smaller
than the largest unit (specified in subsection (l) of this Section) contained
in the package shall not equal or exceed the number of such smaller units in
the next larger unit so specified (for example, instead of "1 quart 16
fluid ounces" the statement shall be "1½ quarts" or "1
quart 1 pint").
2) In the case of a drug with respect to which there exists an
established custom of stating the quantity of the contents as a fraction of a
unit, which unit is larger than the quantity contained in the package, or as
units smaller than the largest unit contained therein, the statement may be
made in accordance with such custom if it is informative to consumers.
o) The statement of the quantity of a drug or device shall
express the minimum quantity, or the average quantity, of the contents of the
packages. If the statement is not so qualified as to show definitely that the
quantity expressed is the minimum quantity, the statement, except in the case
of ampules, shall be considered to express the average quantity. The statement
of the quantity of a drug in ampules shall be considered to express the minimum
quantity.
p) Where the statement expresses the minimum quantity, no
variation below the stated minimum shall be permitted except variations below
the stated weight or measure of a drug caused by ordinary and customary
exposure, after such drug is introduced into commerce, to conditions which
normally occur in good distribution practice and which unavoidably result in
decreased weight or measure. Variations above the stated minimum shall not be
unreasonably large. In the case of a liquid drug in ampules the variation above
the stated measure shall comply with the excess volume prescribed by the
National Formulary for filling of ampules.
q) Where the statement does not express the minimum quantity:
1) Variations from the stated weight or measure of a drug shall
be permitted when caused by ordinary and customary exposure after such drug is
introduced into commerce, to conditions which normally occur in good
distribution practice and which unavoidably result in change of weight or
measure;
2) Variations from the stated weight, measure or numerical count
of a drug or device shall be permitted when caused by unavoidable deviations in
weighing, measuring or counting the contents of individual packages which occur
in good packing practice. But, under this paragraph, variations shall not be
permitted to such extent that the average of the quantities in the packages
comprising a shipment or other delivery of the drug or device is below the
quantity stated and no unreasonable shortage in any package shall be permitted,
even though coverages in other packages in the same shipment or delivery
compensate for such shortage.
r) The extent of variations from the stated quantity of the
contents permissible under subsections (p) and (q) of this Section in the case
of each shipment or other delivery shall be determined by the facts in such
case.
s) A drug or device shall be exempt from compliance with the
requirements of Section 15(b)(2) of the Act if:
1) The statement of the quantity of the contents, as expressed in
terms applicable to such drug or device under the provisions of subsection
(j)(2) of this Section, together with all other words, statements and
information required by or under authority of the Act to appear on the label of
such drug or device, cannot, because of insufficient label space, be so placed
on the label as to comply with requirements of Section 15(c) of the Act and
regulations promulgated thereunder, or
2) The quantity of the contents of the package, as expressed in
terms of numerical count in compliance with subsections (l)(2) or (m) of this
Section is less than six units, and such units can be easily counted without
opening the package, or
3) It is an ointment, is labeled "Sample" or
"Physician's Sample," or with a substantially similar statement, and
the contents of the package do not weigh more than 8 grams.
t) Drugs and Devices: Forms of Making Required Statements.
A word,
statement or other information required by or under authority of the Act to
appear on the label may lack that prominence and conspicuousness required by
Section 15(c) of the Act by reason (among other reasons) of:
1) The failure of such word, statement or information to appear
on the part or panel of the label which is presented or displayed under
customary conditions of the purchase;
2) The failure of such word, statement or information to appear
on two or more parts or panels of the label, each of which has sufficient space
therefor, and each of which is so designed as to render it likely to be, under
customary conditions of purchase, the part or panel displayed;
3) The failure of the label to extend over the area of the
container or package available for such extension, so as to provide sufficient
label space for the prominent placing of such word, statement or information;
4) Insufficiency of label space (for the prominent placing of
such word, statement or information) resulting from the use of label space for
any word, statement, design or device which is not required by or under
authority of the Act to appear on the label;
5) Insufficiency of label space (for the prominent placing of
such word, statement or information) resulting from the use of label space to
give materially greater conspicuousness to any other word, statement or
information, or to any design or device; or
6) Smallness or style of type in which such word, statement or
information appears, insufficient background contrast, obscuring designs or
vignettes, or crowding with other written, printed or graphic matter.
u) No exemption depending on insufficiency of label space, as
prescribed in regulations promulgated under Section 15(b) or (e) of the Act,
shall apply if such insufficiency is caused by:
1) The use of label space for any word, statement, design or
device which is not required by or under authority of the Act to appear on the
label;
2) The use of label space to give greater conspicuousness to any
word, statement or other information than is required by Section 15(c) of the
Act; or
3) The use of label space for any representation in a foreign
language.
v)
1) All words, statements and other information required by or
under authority of the Act to appear on the label or labeling shall appear
thereon in the English language;
2) If the label contains any representation in a foreign
language, all words, statement and other information required by or under
authority of the Act to appear on the label shall appear thereon in the foreign
language;
3) If the labeling contains any representation in a foreign
language, all words, statements and other information required by or under
authority of the Act to appear on the label or labeling shall appear on the
labeling in the foreign language.
w) Drugs: Statement of Ingredients.
The ingredient
information required by Section 15(e) of the Act shall appear together, without
any intervening written, printed or graphic matter, except the proprietary
names of ingredients, which may be included with the listing of established
names, and such statements as "Warning – May be Habit Forming" that
are specifically required for certain ingredients by the Act or regulations
promulgated thereunder.
x) The term "ingredient" applies to any substance in
the drug, whether added to the formulation as a single substance or in
admixture with other substances.
y) The labeling of a drug may be misleading by reason (among
other reasons) of:
1) The order in which the names of the ingredients present in the
drug appear in the labeling, or the relative prominence otherwise given such
names;
2) Failure to reveal the proportion of, or other fact with
respect to, an ingredient present in such drug, when such proportion or other
fact is material in the light of the representation that such ingredient is
present in such drug;
3) The employment of a fanciful proprietary name for a drug or
ingredient in such a manner as to imply that the drug or ingredient has some
unique effectiveness or composition when, in fact, the drug or ingredient is a
common substance, the limitations of which are readily recognized when the drug
or ingredient is listed by its established name;
4) The featuring in the labeling of inert or inactive ingredients
in a manner that creates an impression of value greater than their true
functional role in the formulation;
5) Designation of a drug or ingredient by a proprietary name
that, because of similarity in spelling or pronunciation, may be confused with
the proprietary name or the established name of a different drug or ingredient.
z)
1) If the drug is in tablet or capsule form or other unit dosage
form, any statement of the quantity of an ingredient contained therein shall
express the quantity of such ingredient in each such unit. If the drug is not
in unit dosage form, any statement of the quantity of an ingredient contained
therein shall express the amount of such ingredient in a specified unit of
weight or measure of the drug, or the percentage of such ingredient in such
drug. Such statements shall be in terms that are informative to licensed
practitioners, in the case of a prescription drug, and to the layman, in the
case of a nonprescription drug.
2) A statement of the percentage of an ingredient in a drug
shall, if the term "percent" is used without qualification, mean
percent weight-in-weight, if the ingredient and the drug are both solids, or if
the ingredient is a liquid and the drug is a solid; percent weight-in-volume at
68º F. (20º C.), if the ingredient is a solid and the drug is a liquid; and
percent volume-in-volume at 68º F. (20º C.), if both the ingredient and the
drug are liquids, except that alcohol shall be stated in terms of percent
volume of absolute alcohol at 60º F. (15.56º C.).
aa) A derivative or preparation of a substance named in Section
15(c) of the Act is an article derived or prepared from such substance by any
method, including actual or theoretical chemical action.
bb) If an ingredient is a derivative or preparation of a substance
specifically named in Section 15(e) of the Act and the established name of such
ingredient does not indicate that it is a derivative or preparation of the
parent substance named in Section 15(e) of the Act, the labeling shall, in
conjunction with the listing of the established name of such ingredient,
declare that such article is a derivative or preparation of such parent
substance.
cc)
1) If the label or labeling of a prescription drug bears a
proprietary name or designation for the drug or any ingredient thereof, the
established name, if such there be, corresponding to such proprietary name or
designation, shall accompany each appearance of such proprietary name or
designation. The established name shall be placed in direct conjunction with
the proprietary name or designation, and the relationship between the
proprietary name or designation and the established name shall be made clear by
use of a phrase such as "brand of," preceding the established name,
or by brackets surrounding the established name.
2) The established name shall be printed in letters that are at
least half as large as the letters comprising the proprietary name or
designation with which it is jointed, and the established name shall have a
prominence commensurate with the prominence with which such proprietary name or
designation appears, taking into account all pertinent factors, including
typography, layout, contrast and other printing features.
dd)
1) In the case of a prescription drug containing two or more
active ingredients, if the label bears a proprietary name or designation for
such mixture and there is no established name corresponding to such proprietary
name or designation, the quantitative ingredient information required on the
label by Section 15(e) of the Act shall be placed in direct conjunction with
the most prominent display of the proprietary name or designation. The
prominence of the quantitative ingredient information shall bear a reasonable
relationship to the prominence of the proprietary name.
2) If the drug is packaged in a container too small to bear the
quantitative ingredient information on the main display panel, the quantitative
ingredient information required by Section 15(e) of the Act may appear
elsewhere on the label, even thought the proprietary name or designation
appears on the main display panel of the label; but side-or-back-panel
placement shall in this case be so arranged and printed as to provide size and
prominence of display reasonably related to the size and prominence of the
front-panel display.
ee) A drug packaged in a container too small or otherwise unable to
accommodate a label with sufficient space to bear the information required for
compliance with Section 15(e)(1)(ii) of the Act shall be exempt from compliance
with those clauses; Provided that:
1) The label bears:
A) The proprietary name of the drug;
B) The established name, if such there be, of the drug;
C) An identifying lot or control number; and
D) The name of the manufacturer, packer or distributor of the
drug; AND
2) All the information required to appear on the label by the Act
and the regulations promulgated thereunder appears on the carton or other outer
container or wrapper if such carton, outer container or wrapper has sufficient
space to bear such information, or such complete label information appears on a
leaflet with the package.
ff) Prescription: Drug Advertisements.
All
advertisements for prescription drugs shall be subject to all regulations
issued under the Federal Food, Drug and Cosmetic Act (the Federal Act), as
amended (21 U.S.C. 352), including all regulations relating to but not limited
to Section 502(n) of such Federal Act.
gg) An advertisement issued or caused to be issued by the
manufacturer, packer or distributor of the drug promoted by the advertisement
and which is not in compliance with Section 502(n) of the Federal Food, Drug
and Cosmetic Act (the Federal Act), as amended (21 U.S.C. 352), and the
applicable regulations thereunder shall cause stocks of such drug in possession
of the person responsible for issuing or causing the issuance of the
advertisement, and stocks of the drug distributed by such person and still in
the channels of commerce, to be misbranded under Section 15(n) of the Act.
hh) Brochures, mailing pieces, detailing pieces, file cards,
bulletins, price lists, catalogs, house organs, literature reprints and similar
pieces of printed matter concerning a drug and which are disseminated by or on
behalf of its manufacturer, packer or distributor, including reference
publications for use by medical practitioners, pharmacists or nurses,
containing drug information supplied by the manufacturer, packer or distributor
of the drug, are regarded as labeling not subject to Section 15(n) of the Act
but subject to the labeling requirement of subsections (w) through (ee) inclusive
and subsections (ii) through (vv) inclusive of this Section.
ii) Drugs and Devices: Directions For Use.
ADEQUATE
DIRECTIONS FOR USE. "Adequate directions for use" means directions
under which the layman can use a drug or device safely and for the purposes for
which it is intended. Directions for use may be inadequate because (among
other reasons) of omission, in whole or in part, or incorrect specification of:
1) Statements of all conditions, purposes or uses for which such
drug or device is intended, including conditions, purposes or uses for which it
is prescribed, recommended or suggested in its oral, written, printed or
graphic advertising, and conditions, purposes or uses for which the drug or
device is commonly used; except that such statements shall not refer to
conditions, uses or purposes for which the drug or device can be safely used
only under the supervision of a practitioner licensed by law and for which it
is advertised solely to such practitioner.
2) Quantity of dose (including usual quantities for each of the
uses for which it is intended and usual quantities for persons of different
ages and different physical conditions).
3) Frequency of administration or application.
4) Duration of administration or application.
5) Time of administration or application (in relation to time of
meals, time of onset of symptoms, or other time factors).
6) Route of method of administration or application.
7) Preparation for use (shaking, dilution, adjustment of
temperature, or other manipulation or process).
jj) Exemption for Prescription Drugs.
A drug subject
to the requirements of Section 16(a) of the Act shall be exempt from Section
15(f)(1) if all the following conditions are met:
1) The drug is:
A)
i) In the possession of a person (or his agents or employees)
regularly and lawfully engaged in the manufacture, transportation, storage or
wholesale distribution of prescription drugs; or
ii) In the possession of a retail, hospital or clinic pharmacy,
or a public health agency, regularly and lawfully engaged in dispensing
prescription drugs; or
iii) In the possession of a practitioner licensed by law to
administer or prescribe such drugs; and
B) It is to be dispensed in accordance with Section 16 of the Act.
2) The label of the drug bears:
A) The statement "Caution: Federal law prohibits dispensing
without prescription" or "Caution: State law prohibits dispensing
without prescription"; and
B) The recommended or usual dosage; and
C) The route of administration, if it is not for oral use; and
D) The quantity or proportion of each active ingredient, as well
as the information required by Section 15(d) and (e) of the Act; and
E) If it is for other than oral use, the names of all inactive
ingredients, except that:
i) Flavorings and perfumes may be designated as such without
naming their components;
ii) Color additives may be designated as coloring without naming
specific color components unless the naming of such components is required by a
color additive regulation adopted under the Federal Act;
iii) Trace amounts of harmless substances added solely for
individual product identification need not be named;
F) If it is intended for administration by parenteral injection,
the quantity of proportion of all inactive ingredients, except that ingredients
added to adjust the pH or to make the drug isotonic may be declared by name and
a statement of their effect; and if the vehicle is water for injection it need
not be named;
G) An identifying lot or control number from which it is possible
to determine the complete manufacturing history of the package of the drug;
H) Provided, however, that in the case of containers too small or
otherwise unable to accommodate a label with sufficient space to bear all such
information, but which are packaged within an outer container from which they
are removed for dispensing or use, the information required by subsections
(jj)(2)(B), (C) and (E) above may be contained in other labeling on or within
the package from which it is to be dispensed, and the information referred to
in subsection (jj)(2)(A) above may be placed on such outer container only, and
the information required by subsection (jj)(2)(G) above may be on the crimp of
the dispensing tube.
3)
A) Labeling on or within the package from which the drug is to be
dispensed bears adequate information for its use, including indications,
effects, dosages, routes, methods, and frequency and duration of
administrations, and any relevant hazards, contraindications, side effects and
precautions under which practitioners licensed by law to administer the drug
can use the drug safely and for the purpose for which it is intended, including
all purposes for which it is advertised or represented; and
B) If the article is subject to Section 17 of the Act or Section
506 or 507 of the Federal Act, the labeling bearing such information is the
labeling authorized by the approved new-drug application or required as a
condition for the certification or the exemption from certification
requirements applicable to preparations of insulin or antibiotic drugs:
Provided, however, that the information required by subsection (jj)(3)(A) above
may be omitted from the dispensing package if, but only if, the article is a
drug for which directions, hazards, warnings, and use information are commonly
known to practitioners licensed by law to administer the drug. Upon written
request, stating reasonable grounds therefor, the Director will offer an
opinion on a proposal to omit such information from the dispensing package
under this proviso.
4) Any labeling, as defined in Section 1.10 of the Act, whether
or not it is on or within a package from which the drug is to be dispensed,
distributed by or on behalf of the manufacturer, packer or distributor of the
drug, that furnishes or purports to furnish information for use or which
prescribes, recommends or suggests a dosage for the use of the drug (other than
dose information required by subsection (jj)(2)(B) and subsection (kk) of this
Section) contains:
A) Adequate information for such use, including indications,
effects, dosages, routes, methods, and frequency and duration of administration
and any relevant hazards, contraindications, side effects and precautions,
under which practitioners licensed by law to administer the drug can use the
drug safely and for the purposes for which it is intended, including all
conditions for which it is advertised or represented; and if the article is
subject to Section 15 of the Act or Section 506 or 507 of the Federal Act, the
labeling providing such information is substantially the same as the labeling
authorized by the approved new-drug application or required as a condition for
its certification, or exemption from certification; and
B) The same information concerning the ingredients of the drug as
appears on the label and labeling on or within the package from which the drug
is to be dispensed; Provided, however, that the information required by
subsections (jj)(4)(A) and (B) of this Section is not required on the so-called
reminder-piece labeling which calls attention to the name of the drug but does
not include indications or dosage recommendations for use of the drug.
5) All labeling, except labels and cartons, bearing information
for use of the drug also bears the date of the issuance or the date of the
latest revision of such labeling.
kk) Exemption for Veterinary Drugs.
A drug
intended for veterinary use which, because of toxicity or other potentiality
for harmful effect, or the method of its use, is not safe for animal use except
under the supervision of a licensed veterinarian, and hence for which
"adequate directions for use" cannot be prepared, shall be exempt from
Section 15(f)(1) of the Act if all the following conditions are met:
1) The drug is:
A) In the possession of a person (or his agents or employees)
regularly and lawfully engaged in the manufacture, transportation, storage or
wholesale or retail distribution of veterinary drugs and is to be sold only to
or on the prescription or other order of a licensed veterinarian for use in the
course of his professional practice; or
B) In the possession of a licensed veterinarian for use in the
course of his professional practice.
2) The label of the drug bears:
A) The statement "Caution: Federal law restricts this drug
to sale by or on the order of a licensed veterinarian" or "Caution:
State law restricts this drug to sale by or on the order of a licensed veterinarian";
and
B) The recommended or usual dosage; and
C) The route of administration, if it is not for oral use; and
D) The quantity or proportion of each active ingredient as well as
the information required by Section 15(e) of the Act; and
E) If it is for other than oral use, the names of all inactive
ingredients, except that:
i) Flavorings and perfumes may be designated as such without
naming their components;
ii) Color additives may be designated as coloring without naming
specific color components unless the naming of such components is required by a
color additive regulation adopted under the Federal Act;
iii) Trace amounts of harmless substances added solely for
individual product identification need not be named;
F) If it is intended for administration by parenteral injection,
the quantity of proportion of all inactive ingredients, except that ingredients
added to adjust the pH or to make the drug isotonic may be declared by name and
a statement of their effect; and if the vehicle is water for injection it need
not be named;
G) An identifying lot or control number from which it is possible
to determine the complete manufacturing history of the package of the drug;
Provided, however, that in the case of containers too small or otherwise unable
to accommodate a label with sufficient space to bear all such information, but
which are packaged within an outer container from which they are removed for
dispensing or use, the information required by subsections (kk)(2)(B), (C) and
(E) above may be contained in other labeling on or within the package from
which it is to be so dispensed, and the information referred to in subsection
(kk)(2)(A) above may be placed on such outer container only, and the
information required by this subsection (kk)(2)(G) may be on the crimp of the
dispensing tube.
3)
A) Labeling on or within the package from which the drug is to be
dispensed bears adequate information for its use, including indications,
effects, dosages, routes, methods, and frequency and duration of
administrations, and any relevant hazards, contraindications, side effects and
precautions under which veterinarians licensed by law to administer the drug
can use the drug safely and for the purpose for which it is intended, including
all purposes for which it is advertised or represented; and
B) If the article is subject to Section 17 of the Act or Section
507 of the Federal Act, the labeling bearing such information is the labeling
authorized by the approved new-drug application or required as a condition for
the certification or the exemption from certification requirements applicable
to preparations of antibiotic drugs: Provided, however, that the information
required by subsection (kk)(3)(A) above may be omitted from the dispensing
package if, but only if, the article is a drug for which directions, hazards,
warnings, and use information are commonly known to veterinarians licensed by
law to administer the drug. Upon written request, stating reasonable grounds
therefor, the Director will offer an opinion on a proposal to omit such
information from the dispensing package under this proviso.
4) Any labeling, as defined in Section 2.10 of the Act, whether
or not it is on or within a package from which the drug is to be dispensed,
distributed by or on behalf of the manufacturer, packer or distributor of the
drug, that furnishes or purports to furnish information for use or which
prescribes, recommends or suggests a dosage for the use of the drug (other than
dose information required by subsection (kk)(2)(B) and subsection (ll) of this
Section) contains:
A) Adequate information for such use, including indications,
effects, dosages, routes, methods, and frequency and duration of administration
and any relevant hazards, contraindications, side effects and precautions, and
including information relevant to compliance with the food additive provisions
of the Act, under which veterinarians licensed by law to administer the drug
can use the drug safely and for the purposes for which it is intended,
including all conditions for which it is advertised or represented; and if the
article is subject to Section 17 of the Act or Section 507 of the Federal Act,
the labeling providing such information is substantially the same as the
labeling authorized by the approved new-drug application or required as a
condition for its certification, or exemption from certification; and
B) The same information concerning the ingredients of the drug as
appears on the label and labeling on or within the package from which the drug
is to be dispensed; Provided, however, that the information required by
subsections (kk)(4)(A) and (B) of this Section is not required on the so-called
reminder-piece labeling which calls attention to the name of the drug but does
not include indications or dosage recommendations for use of the drug.
5) All labeling, except labels and cartons, bearing information
of use of the drug also bears the date of the issuance or the date of the
latest revision of such labeling.
6) A prescription drug intended for both human and veterinary use
shall comply with subsections (z) and (kk)(4) and (5) of this Section.
ll) Exemption for Prescription Devices.
A device
which, because of any potentiality for harmful effect, or the method of its
use, or the collateral measures necessary to its use, is not safe except under
the supervision of a practitioner licensed by law to direct the use of such
device, and hence for which "adequate directions for use" cannot be
prepared, shall be exempt from Section 15(f)(1) of the Act if all the following
conditions are met:
1) The device is:
A)
i) In the possession of a person (or his agents or employees)
regularly and lawfully engaged in the manufacture, transportation, storage or
wholesale or retail distribution of such device; or
ii) In the possession of a practitioner, such as physicians,
dentists and veterinarians, licensed by law to use or order the use of such
device; and
B) Is to be sold only to or on the prescription or other order of
such practitioner for use in the course of his practice.
2) The label of the device (other than surgical instruments)
bears:
A) The statement "Caution: Federal law restricts this device
to sale by or on the order of a ___________" or "Caution: State law
restricts this device to sale by or on the order of a ___________," the
blank to be filled with the word "physician," "dentist,"
"veterinarian," or with the descriptive designation of any other
practitioner licensed by law of the State to use or order the use of the
device; and
B) The method of its application or use.
3) Labeling on or within the package from which the device is to
be dispensed bears information for use, including indications, effects, routes,
methods, and frequency and duration of administration, and any relevant
hazards, contraindications, side effects and precautions under which
practitioners licensed by law to administer the device can use the device
safely and for the purpose for which it is intended, including all purposes for
which it is advertised or represented: Provided, however, that such
information may be omitted from the dispensing package if, but only if, the
article is a device for which directions, hazards, warnings and other
information are commonly known to practitioners licensed by law to use the
device. Upon written request, stating reasonable grounds therefor, the
Director will offer an opinion on a proposal to omit such information from the
dispensing package under this proviso.
4) Any labeling, as defined in Section 2.10 of the Act, whether
or not it is on or within a package from which the device is to be dispensed,
distributed by or on behalf of the manufacturer, packer or distributor of the
device, that furnishes or purports to furnish information for use of the device
contains adequate information for such use, including indications, effects,
routes, methods, and frequency and duration of administration and any relevant
hazards, contraindications, side effects and precautions, under which
practitioners licensed by law to employ the device can use the device safely
and for the purpose for which it is intended, including all purposes for which
it is advertised or represented. This information will not be required on
so-called reminder-piece labeling which calls attention to the name of the
device but does not include indications or other use information.
5) All labeling, except labels and cartons, bearing information
for use of the device also bears the date of the issuance or the date of the
latest revision of such labeling.
mm) Exemption for Retail Veterinary Drugs and Prescription Devices.
A drug or
device subject to subsections (kk) or (ll) of this Section shall be exempt at
the time of delivery to the ultimate purchaser or user from Section 15(f)(1) of
the Act if it is delivered by a licensed practitioner in the course of his
professional practice or upon a prescription or other order lawfully issued in
the course of his professional practice, with labeling bearing the name and
address of such licensed practitioner and the directions for use and cautionary
statements, if any, contained in such order.
nn) Exemption for New Drugs.
A new drug
shall be exempt from Section 15(f)(1) of the Act:
1) To the extent to which such exemption is claimed in an
approved application with respect to such drug under Section 17 of the Act; or
2)
A) If no application under Section 17 of the Act is approved with
respect to such drug but it complies with Section 505(i) of the Federal Act and
regulations thereunder.
B) No exemption shall apply to any other drug which would be a new
drug if its labeling bore representations for its intended use.
oo) Exemption For Drugs or Devices When Directions Are Commonly Known.
A drug or
device shall be exempt from Section 15(f)(1) of the Act insofar as adequate
directions for common uses thereof are known to the ordinary individual.
pp) Exemptions For Inactive Ingredients.
A harmless
drug that is ordinarily used as an inactive ingredient, such as coloring,
emulsifier, excipient, flavoring, lubricant, preservative or solvent, in the
preparation of other drugs, shall be exempt from Section 15(f)(1) of the Act.
This exemption shall not apply to any substance intended for a use which
results in the preparation of a new drug, unless an approved new-drug
application provides for such use.
qq) Exemption for Diagnostic Reagents.
A drug
intended solely for use in the professional diagnosis of disease and which is
generally recognized by qualified experts as useful for that purpose shall be
exempt from Section 15(f)(1) of the Act if it label bears the statement
"Diagnostic reagent – For professional use only."
rr) Exemption for Prescription Chemicals and Other Prescription
Components.
A drug
prepared, packaged and primarily sold as a prescription chemical or other
component for use by registered pharmacists in compounding prescriptions or for
dispensing in dosage unit form upon prescriptions shall be exempt from Section
15(f)(1) of the Act if all the following conditions are met:
1) The drug is an official liquid acid or official liquid alkali
or is not a liquid solution, emulsion, suspension, tablet, capsule or other
dosage unit form; and
2) The label of the drug bears:
A) The statement "For prescription compounding," and
B) If in substantially all dosage forms in which it may be
dispensed it is subject to Section 16(a) of the Act, the statement
"Caution: Federal law prohibits dispensing without prescription" or
"Caution: State law prohibits dispensing without prescription," or
C)
i) If it is not subject to Section 16(a) of the Act and is by
custom among retail pharmacists sold in or from the interstate package for use
by consumers, "adequate directions for use" in the conditions for
which it is so sold.
ii) Provided, however, that the information referred to in
subsection (rr)(2)(C)(i) above may be contained in the labeling on or within
the package from which it is to be dispensed.
3) This exemption shall not apply to any substance intended for
use in compounding which results in a new drug, unless an approved new-drug
application covers such use of the drug in compounding prescriptions.
ss) Exemption for Processing, Repacking or Manufacture.
A drug in a
bulk package (except tablets, capsules or other dosage unit forms) or a device
intended for processing, repacking or use in the manufacture of another drug or
device shall be exempt from Section 15(f)(1) of the Act if its label bears the
statement "Caution: For manufacture, processing or repacking" and,
if in substantially all dosage forms in which it may be dispensed it is subject
to Section 16(a) of the Act, the statement "Caution: Federal law
prohibits dispensing without prescription" or "Caution: State law
prohibits dispensing without prescription." This exemption and the
exemption under subsection (rr) of this Section may be claimed for the same
article. But the exemption shall not apply to a substance intended for a use
in manufacture, processing or repacking which causes the finished article to be
a new drug, unless:
1) An approved new-drug application held by the person preparing
the dosage form or drug for dispensing covers the production and delivery to
him of such substance; or
2) If no application is approved with respect to such new drug,
the label statement "Caution: For manufacturing, processing or
repacking" is immediately supplemented by the words "in the
preparation of a new drug limited by Federal law to investigational use"
or "in the preparation of a new drug limited by Illinois law to
investigational use," and the delivery is made for use only in the
manufacture of such new drug limited to investigation use.
tt) Exemption For Drugs and Devices For Use in Teaching, Law
Enforcement, Research and Analysis.
A drug or
device subject to subsections (jj), (kk) or (ll) of this Section shall be
exempt from Section 15(f)(1) of the Act if shipped or sold to, or in the
possession of, persons regularly and lawfully engaged in instruction in
pharmacy, chemistry or medicine not involving clinical use, or engaged in law
enforcement, or in research not involving clinical use, or in chemical
analysis, or physical testing, and is to be used only for such instruction, law
enforcement, research, analysis or testing.
uu) Expiration of Exemptions.
1) If a shipment or delivery, or any part, of a drug or device
which is exempt under the regulations in this Section is made to a person in
whose possession the article is not exempt, or is made for any purpose other
than those specified, such exemption shall expire, with respect to such
shipment or delivery or part, at the beginning of that shipment or delivery.
The causing of an exemption to expire shall be considered an act which results in
such drug or device being misbranded unless it is disposed of under
circumstances in which it ceases to be a drug or device.
2) The exemptions conferred by subsections (pp), (qq), (rr), (ss)
and (tt) of this Section shall continue until the drugs or devices are used for
the purposes for which they are exempted, or until they are relabeled to comply
with Section 15(f)(1) of the Act. If, however, the drug is converted,
compounded or manufactured into a dosage form limited to prescription
dispensing, no exemption shall thereafter apply to the article unless the
dosage form is labeled as required by Section 16 of the Act and subsections
(jj), (kk) or (ll) of this Section.
vv) Intended Uses.
The words
"intended uses" or words of similar import in subsections (ii), (nn),
(pp), (qq), (rr) and (ss) of this Section refer to the objective intent of the
persons legally responsible for the labeling of drugs and devices. The intent
is determined by such persons' expressions or may be shown by the circumstances
surrounding the distribution of the article. This objective intent may, for
example, be shown by labeling claims, advertising matter, or oral or written
statements by such persons or their representatives. It may be shown by the
circumstances that the article is, with the knowledge of such persons or their
representatives, offered and used for a purpose for which it is neither labeled
nor advertised. The intended uses of an article may change after it has been
introduced into commerce by its manufacturer. If, for example, a packer,
distributor or seller intends an article for different uses than those intended
by the person from whom he received the drug, such packer, distributor or
seller is required to supply adequate labeling in accordance with the new intended
uses. But if a manufacturer knows, or has knowledge of facts that would give
him notice, that a drug or device introduced into commerce by him is to be used
for conditions, purposes or uses other than the ones for which he offers it, he
is required to provide adequate labeling for such a drug which accords with
such other uses to which the article is to be put.
ww) Drugs and Devices: Exemptions.
1) Except as provided by subsections (ww)(2) and (3) below, a
shipment or other delivery of a drug or device which is, in accordance with the
practice of the trade, to be processed, labeled or repacked in substantial
quantity at an establishment other than that where originally processed or
packed, shall be exempt, during the time of introduction into and movement in
commerce and the time of holding in such establishment, from compliance with
the labeling and packaging requirements of Sections 14(b) and 15(b), (d), (e),
(f) and (g) of the Act if:
A) The person who introduced such shipment or delivery into
commerce is the operator of the establishment where such drug or device is to
be processed, labeled or repacked; or
B) In case such person is not such operator, such shipment or
delivery is made to such establishment under a written agreement, signed by and
containing the post office addresses of such person and such operator, and
containing such specifications for the processing, labeling or repacking, as
the case may be, of such drug or device in such establishment as will insure,
if such specifications are followed, that such drug or device will not be
adulterated or misbranded within the meaning of the Act upon completion of such
processing, labeling or repacking. Such person and such operator shall each
keep a copy of such agreement until two years after the final shipment or
delivery of such drug or device from such establishment, and shall make such
copies available for inspection at any reasonable hour to any officer or
employee of the Illinois Department of Public Health who requests them.
2) An exemption of a shipment or other delivery of a drug or
device under subsection (ww)(1)(A) above shall, at the beginning of the act of
removing such shipment or delivery, or any part, from such establishment,
become void ab initio if the drug or device comprising such shipment, delivery,
or part, is adulterated or misbranded within the meaning of the act when so
removed.
3) An exemption of a shipment or other delivery of a drug or
device under subsection (ww)(1)(B) above shall become void ab initio with
respect to the person who introduced such shipment or delivery into commerce
upon refusal by such person to make available for inspection a copy of the
agreement, as required by such subsection.
4) An exemption of a shipment or other delivery of a drug or
device under subsection (ww)(1)(B) above shall expire:
A) At the beginning of the act of removing such shipment or
delivery, or any part, from such establishment if the drug or device comprising
such shipment, delivery, or part, is adulterated or misbranded within the
meaning of the act when so removed; or
B) Upon refusal by the operator of the establishment where such
drug or device is to be processed, labeled or repacked, to make available for inspection
a copy of the agreement, as required by such clause.
5) Except as provided in subsections (ww)(7) and (8) below, a
shipment or other delivery of a drug which is subject to Section 507 of the
Federal Act and which is, in accordance with the practice of the trade, other
than that where originally processed or packed, shall be exempt from compliance
with the labeling requirements of Section 15(f) of the Act during the time such
drug is also exempt from the requirements of Section 15(1) of the Act.
6) Except as provided by subsections (ww)(7) and (8) below, a
shipment or other delivery of a drug which is subject to Section 507 of the
Federal Act and which is, in accordance with the practice of the trade, to be
labeled in substantial quantity at an establishment other than that where
originally processed or packed shall be exempt from compliance with the labeling
requirements of Section 15(b), (e) and (f) of the Act during the time such drug
is also exempt from the requirements of Section 15(1) of the Act if the words,
statements and other information required by Section 15(b) and (e) of the Act
appear on each shipping container of such drug.
7) In case the person who introduced such shipment or other
delivery into commerce is the operator of the establishment where such drug is
to be processed, labeled or repacked, an exemption of such shipment or delivery
under subsections (ww)(5) and (6) above shall become void at the beginning of
the act or removing such shipment or delivery or any part from such
establishment if the drug comprising such shipment, delivery, or part, is
adulterated or misbranded within the meaning of the act when so removed.
8) In case the person who introduced such shipment or delivery
into interstate commerce is not the operator of the establishment where such
drug is to be processed, labeled or repacked, an exemption of a shipment or
other delivery of such drug under subsections (ww)(5) and (6) above shall
expire at the beginning of the act or removing such shipment or delivery or any
part from such establishment if the drug comprising such shipment, delivery, or
part, is adulterated or misbranded within the meaning of the act when so
removed.
xx) Definition of Term "Insulin."
For the
purposes of Section 15(k) of the Act and Section 506 of the Federal Act.
1) The term "insulin" as used therein means the active
principle of pancreas which affects the metabolism of carbohydrates in the
animal body and which is of value in the treatment of diabetes mellitus.
2) The following substances, when they are intended for use in
the manufacturing of insulin-containing drugs that will subsequently be
submitted for certification, shall not be considered to be subject to
certification as "drugs composed wholly or partly of insulin":
A) Pancreas glands; and
B) Materials prepared from pancreas glands, such as "sale
cake" and "isoelectric precipitate," which materials must be
subjected to further purification in order to meet the standards of purity
established by 21 CFR 429 of the Federal Regulations.